The Pathophysiology and Impact of Inflammation in Nonscarred Renal Interstitium: The Banff i Lesion.
Interstitial inflammation (i-INT) is the driver of T cell rejection (TCMR). Its causes, pathophysiology, kinetics, and outcomes are poorly documented. The role of i-INT was evaluated in 2055 biopsies from 775 renal transplant recipients. i-INT was present in 374 (18.2% prevalence) from acute and subclinical rejection (67.4%); IF/TA (14.4%); BK virus nephropathy (BKVAN) 9.9%; and acute tubular necrosis (ATN with i-INT) in 5.9% of cases. i-INT was predicted by prior TCMR and BKVAN, HLA mismatch, cyclosporine therapy, and indication biopsy for dysfunction. It correlated with tubulitis, arteritis, and antibody markers within concurrent histology (P<0.001). After treatment, renal functional recovery was best with histological ATN, milder i-INT, and early posttransplant biopsy times. The initial histological improvement of inflammation depended on baseline i-INT severity. Complete resolution to Banff i0 was predicted by early biopsy time, anti-lymphocyte therapy, recipient age, and medication compliance (all P<0.001). Clearance i-INT was followed by delayed resolution of tubulitis (P<0.001). i-INT was associated with histological ATN, renal dysfunction, and increased incident fibrosis on sequential pathology. Progressive fibrosis following related-rejection i-INT was dependent on tubulitis using multivariable analysis. In contrast, fibrogenesis after BKVAN or ATN was unrelated to inflammation. i-INT cases were followed by recurrent rejection in 35.3%, increased graft loss, and greater patient mortality. Multiple complementary outcome analyses determined the optimal lower diagnostic threshold for inflammation was Banff i1 score. i-INT is a heterogeneous pathological phenotype that results in adverse functional and structural outcomes, for which active and robust therapy should be considered.